The group's principle activities include developing and commercializing a pipeline of clinically-advanced, peptide-based immunotherapies for adjuvant treatment of HER2-positive cancers. The group's products include NeuVax(TM), NeuVax(TM) for breast and prostate cancer, and NeuVax(TM) + Herceptin(R) for breast cancer. The group operates from United States.